STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[Form 4] ARTIVION, INC. Insider Trading Activity

Filing Impact
(High)
Filing Sentiment
(Negative)
Form Type
4
Rhea-AI Filing Summary

Artivion, Inc. (AORT) President & CEO James P. Mackin reported a Form 4 transaction: the sale of 34,210 shares of common stock at $45.858 on November 13, 2025. The filing states the shares were sold upon RSU vesting to satisfy tax withholding via a “sell to cover” and did not represent a discretionary transaction.

Following the sale, Mackin beneficially owned 800,993 shares, held directly. The transaction code was S, reflecting an open-market or private sale executed to cover withholding obligations tied to equity compensation vesting.

Positive
  • None.
Negative
  • None.

Insights

Routine sell-to-cover by CEO; no thesis change.

Artivion’s CEO reported selling 34,210 shares at $45.858 on Nov 13, 2025. The note specifies the sale occurred upon RSU vesting to fund tax withholding via “sell to cover,” indicating it was not a discretionary trade.

Post-transaction beneficial ownership is 800,993 shares held directly. Such tax-related sales are common with equity awards and do not themselves signal changes in outlook.

Future disclosures in company filings may specify additional equity award vesting or withholding mechanics, but this single event appears administrative in nature.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Mackin James P

(Last) (First) (Middle)
ARTIVION, INC.
1655 ROBERTS BLVD, NW

(Street)
KENNESAW GA 30144

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
ARTIVION, INC. [ AORT ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
President & CEO
3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 11/13/2025 S 34,210(1) D $45.858 800,993 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. These shares were sold upon the vesting of restricted stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction.
Remarks:
/s/ James P. Mackin 11/14/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Artivion (AORT) report on Form 4?

The CEO, James P. Mackin, reported selling 34,210 shares at $45.858 on November 13, 2025.

Why were the Artivion (AORT) shares sold by the CEO?

The filing states the shares were sold upon RSU vesting to satisfy tax withholding via a “sell to cover,” not a discretionary trade.

How many Artivion (AORT) shares does the CEO hold after the sale?

James P. Mackin beneficially owned 800,993 shares following the reported transaction.

What was the transaction code on the Form 4 for Artivion (AORT)?

The transaction code was S, indicating a sale.

What is the CEO’s relationship to Artivion (AORT)?

He is an Officer, serving as President & CEO, and the reported holdings are direct.
Artivion, Inc.

NYSE:AORT

AORT Rankings

AORT Latest News

AORT Latest SEC Filings

AORT Stock Data

2.26B
42.38M
4.5%
89.88%
2.32%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
KENNESAW